AVITA Medical Raises 2026 Revenue Guidance to $89M

AVITA Medical raised its 2026 revenue guidance to a range of $86 million to $89 million, up from its prior forecast of $80 million to $85 million, while reporting narrowing cash burn during a presentation at the Morgan Stanley conference. The upward revision signals improving operational momentum following a difficult 2025 for the commercial-stage regenerative medicine company.

"The problems we had in 2025 were few and fixable," said Cary Vance, Chief Executive Officer, AVITA Medical, in a statement at the conference.

Cash Burn and Breakeven Timeline

Management detailed progress in curtailing operational expenditures during the update. According to the conference transcript, cash burn fell to $3.2 million in the second quarter. Executives further projected that the company will achieve cash flow breakeven by the fourth quarter.

These cost controls follow a restructuring period designed to stabilize margins and align spending with commercial execution. Vance characterized the organization as a healing company anchored by a portfolio of three FDA-approved products targeting advanced wound care and regenerative treatments.

Market Valuation and Share Price Context

In public markets, AVITA Medical Inc (NASDAQ: RCEL) last quoted at $11.02 per share, declining 1.78% from its previous close of $11.22, according to live Finnhub market data.

The revised financial targets and narrowing losses arrive as medical device manufacturers navigate investor scrutiny regarding capital efficiency and pathways to profitability. By accelerating its timeline to cash flow breakeven alongside top-line growth, AVITA aims to reassure markets of its commercial viability following last year's operational hurdles.